Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli

Antimicrob Agents Chemother. 1996 Feb;40(2):491-3. doi: 10.1128/AAC.40.2.491.

Abstract

The gene parC encodes the A subunit of topoisomerase IV of Escherichia coli. Mutations in the parC region analogous to those in the quinolone resistance-determining region of gyrA were investigated in 27 clinical isolates of E. coli for which ciprofloxacin MICs were 0.0007 to 128 micrograms/ml. Of 15 isolates for which ciprofloxacin MICs were > or = 1 microgram/ml, 8 showed a change in the serine residue at position 80 (Ser-80), 4 showed a change in Glu-84, and 3 showed changes in both amino acids. No mutations were detected in 12 clinical isolates for which ciprofloxacin MICs were < or = 0.25 micrograms/ml. These findings suggest that ParC from E. coli may be another target for quinolones and that mutations at residues Ser-80 and Glu-84 may contribute to decreased fluoroquinolone susceptibility.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Antigens, Neoplasm
  • Base Sequence
  • Ciprofloxacin / pharmacology*
  • DNA Topoisomerase IV
  • DNA Topoisomerases, Type II* / genetics*
  • DNA-Binding Proteins
  • Drug Resistance, Microbial / genetics
  • Escherichia coli / drug effects*
  • Escherichia coli / genetics*
  • Escherichia coli / isolation & purification
  • Isoenzymes / genetics
  • Molecular Sequence Data
  • Mutation
  • Sequence Homology, Amino Acid

Substances

  • Anti-Infective Agents
  • Antigens, Neoplasm
  • DNA-Binding Proteins
  • Isoenzymes
  • Ciprofloxacin
  • DNA Topoisomerase IV
  • DNA Topoisomerases, Type II